LISANDO
Lysando focuses on healing and not just treatment, prioritizing people over profits. They develop microbiome-friendly solutions to combat resistant bacteria and hospital germs, emphasizing the importance of microbiome health and innovative, targeted approaches like Artilysin®s to address bacterial infections and antibiotic resistance. Their mission is to create disruptive, microbiome-respecting therapies that redefine infection treatment and support overall health.
Industries
Nr. of Employees
small (1-50)
Products
Precision-engineered antimicrobial proteins for microbiome-targeted therapy
Protein-based therapeutic candidates engineered to selectively remove pathogenic bacteria, disrupt harmful biofilms and act on metabolically inactive/persister bacteria while preserving beneficial microbes.
Precision-engineered antimicrobial proteins for microbiome-targeted therapy
Protein-based therapeutic candidates engineered to selectively remove pathogenic bacteria, disrupt harmful biofilms and act on metabolically inactive/persister bacteria while preserving beneficial microbes.
Services
Partnering with biotech and pharmaceutical organizations to co-develop protein-based antimicrobial candidates and to establish development agreements or licenses.
Provision of therapeutic material donations or emergency supplies to hospitals and clinical partners (documented donation activity in media materials).
Partnering with biotech and pharmaceutical organizations to co-develop protein-based antimicrobial candidates and to establish development agreements or licenses.
Provision of therapeutic material donations or emergency supplies to hospitals and clinical partners (documented donation activity in media materials).
Expertise Areas
- Microbiome therapeutics
- Protein engineering and design
- AI-based drug design
- Antimicrobial resistance solutions
Key Technologies
- AI-driven protein design
- Protein engineering
- Construct/module sequence libraries
- In vitro biofilm and persister assays